Don't forget the next line ...
Romy, this won't hurt a bit ...
Now BEND OVER!
That's an easy one. You asked why else the FDA would grant it (drisapersen) 3 passes? Because there are no other drugs on the market and the push behind getting SOMEthing approved was heavy.
SRPT will file the NDA and be told they need to continue to provide data in the confirmatory study and be granted approval based on that. When the music stops, it will be SRPT sitting pretty in the chair and the drisapersen folks wondering "Why did the music stop?".
Are there any good stocks left? Seems like they are getting beaten bloody at every turn.
ISIS is probably the least beaten down, though it should be at $75+ except for the hatchet job that TheStreet crooks did on it based on misinformation, but that will come clear in time.
I do still like SCMP and SRPT - but this market makes it hard to invest in anything right now.
Certainly should have alleviated the FDAs previous concerns.
Nah, hedge fund managers don't get margin calls the way retail investors do. So for them the short squeeze is just when they finally capitulate and buy shares to cover. They still owe them, they just don't have to put them up any time soon. So, the squeeze part is when they finally decide to cover at $30 or $50 and that forces shares up even higher because now it is artificial demand for shares.
Help me out. I see short interest at 13.26M (32% of float! wow) on April 15th and 12.41M the month prior according to Yahoo Statistics. Is there another source more up to date? I'm not arguing, I'm seeking to see the same numbers you see, but am limited to what I see on Yahoo Key Statistics.
But but but, Obama said he was going to fix all that. He PROMISED. He said he was going after those fat cats on Wall Street. What changed? Did they donate to his campaign? Or Hillary's?
He said there are so many shorts, the squeeze could easily send this over $100/share.
And longandatronggg - I can make #$%$ up too.
Yeah, but seriously, nobody makes a buy/sell decision based on any of the posts here. I'll admit I learn a lot, meaning, someone alerts me to a story and I go pull it from a credible news source like WSJ or CNBC. Many stories I wouldn't even know about had I not seen commentary here first.
But the shorts just bash incessantly and are easily identified and ignored. So they are a lot like a gnat, irritating, but irrelevant.
People need to understand hat most short sellers are hedge funds who can short an UNLIMITED number of shares, shares that don't even exist, and they NEVER get a margin call the way the retail investor does. They can double their short position just to keep a lid on the price.
Why do you think we are at $25 instead of $50 right now? Without the added short selling pressure, this stock would surely be over $50/share.
If it works, it will be the first one to pull it off. The bashers claim there are lots of these types of devices out there, but I can't find one to buy.
All the bashers and negative posts here are starting to make me wonder if something else is going on.
Methinks they protest too much ... Maybe there is more value hidden here that appears.
San Rafael, Calif., April 27 -- BioMarin Pharmaceutical Inc. today announced
completion of the rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for drisapersen, an investigational nonworking exon-skipping drug candidate for the treatment of the largest genetically defined subset of Duchenne muscular dystrophy (DMD). . . . The company intends to also submit an application for registration in the European Union in summer 2015. . . . Drisapersen has been granted Orphan and Fast Track Useless status, as well as Breakthrough Toxic Therapy designation by the FDA.
Amazing how adding just three words can dramatically alter the meaning ...
From the same article:
Today, Sarepta's market cap stands at $800 million. If one assumes a similar market cap as Alexion in six years time, Sarepta has the potential to be a 20-bagger -- if my scenario plays out.
BRENTFORD, UK ( TheStreet) -- Duchenne muscular dystrophy patients treated with GlaxoSmithKline's (GSK - Get Report) experimental drug drisapersen have been hospitalized due to kidney toxicity and low platelet counts, according to a Glaxo scientist who spoke at a research meeting in Rome last Sunday.
Glaxo has disclosed some safety data from early-stage drisapersen clinical trials previously, mainly related to moderate cases of proteinuria (excess protein in the urine) and decreased thrombocytes, which play a role in blood clotting. However, the significance of the adverse events attributed to drisapersen, also known as GSK-2402968, escalated with Sunday's disclosure of hospitalized patients.
Dr. Rohit Batta, global medical leader in Glaxo's neuromuscular rare disease unit, said four Duchenne muscular dystrophy (DMD) patients treated with drisapersen required hospitalization due to thrombocytopenia and that "several" patients with "severe proteinuria" also required hospitalization.